

DAFTAR PUSTAKA

1. Shih IM, Wang Y, Wang TL. The origin of ovarian cancer species and precancerous landscape. *Am J Pathol.* 2021 Jan;191(1):26–39. doi:10.1016/j.ajpath.2020.09.006
2. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. *CA Cancer J Clin.* 2019 Jul 17;69(4):280–304. doi:10.3322/caac.21559
3. Siegel RL, Miller KD, Jemal A. Cancer statistics. *CA Cancer J Clin.* 2018;68(1):7–30.
4. Gaona LP, Adriana L, Medina G, Magaña K. Epidemiology of ovarian cancer. *Chin Clin Oncol.* 2020 Aug 1;9(4). doi:10.21037/cco-20-34 PubMed PMID: 32648448.
5. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2024;74(3):229–63. doi:10.3322/caac.21834 PubMed PMID: 38572751.
6. Badan Penelitian dan Pengembangan Kesehatan KKRI. Laporan Riskesdas 2018 Nasional. 2019.
7. Gersekowski K, Na R, Alsop K, Delahunty R, Goode EL, Cunningham JM, et al. Risk factors for ovarian cancer by brca status: a collaborative case-only analysis. *Cancer Epidemiology Biomarkers and Prevention Journal.* 2024 Apr 1;33(4):1–7. doi:10.1158/1055-9965.EPI-23-0984 PubMed PMID: 38300121.
8. Bullock B, Larkin L, Turker L, Stampler K. Management of the adnexal mass: considerations for the family medicine physician. *Front Med Journals.* 2022 Jul 5;9. doi:10.3389/fmed.2022.913549
9. Song D, Liu T, Han C, Zhang C, Kong W. Differential diagnosis of benign and malignant ovarian tumors with combined tumor and systemic inflammation-related markers. *J Cancer.* 2025 Jul 11;16(10):3192–201. doi:10.7150/jca.112768
10. Reynolds IS, Fichtner M, McNamara DA, Kay EW, Prehn JHM, Burke JP. Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers. *Cancer and Metastasis Reviews.* 2019 Jun 15;38(1–2):237–57. doi:10.1007/s10555-019-09781-w

11. Pant H, Prakash A, Khandelwal R, Pandey S. Correlation of serum CA-125 with histopathological findings in ovarian tumors. *IP Journal of Diagnostic Pathology and Oncology*. 2019 Jun 28;4(2):81–5. doi:10.18231/j.jdpo.2019.016
12. Zhang R, Siu MKY, Ngan HYS, Chan KKL. Molecular biomarkers for the early detection of ovarian cancer. *Int J Mol Sci*. 2022 Oct 10;23(19):12041. doi:10.3390/ijms231912041
13. Liu S, Wu M, Wang F. Research progress in prognostic factors and biomarkers of ovarian cancer. *J Cancer*. 2021;12(13):3976–96. doi:10.7150/jca.47695
14. Jiang Y, Peng F, Chen Y, Fu A, Yang R, Yang Z, et al. UHRF1- mediated HIF-1 α stabilization promotes ovarian cancer through metabolic reprogramming and angiogenesis. *Cell Death Dis*. 2025 Oct 24;16(1):751. doi:10.1038/s41419-025-08033-w
15. Li M, Li L, Cheng X, Li L, Tu K. Hypoxia promotes the growth and metastasis of ovarian cancer cells by suppressing ferroptosis via upregulating SLC2A12. *Exp Cell Res*. 2023 Dec;433(2):113851. doi:10.1016/j.yexcr.2023.113851
16. Nik NN, Vang R, Shih IM, Kurman RJ. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. *Annual Review of Pathology: Mechanisms of Disease*. 2014 Jan 24;9(1):27–45. doi:10.1146/annurev-pathol-020712-163949
17. Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L, et al. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using 2020. *Int J Cancer*. 2022 Nov 30;151(9):1535–41. doi:10.1002/ijc.34002
18. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 May 4;71(3):209–49. doi:10.3322/caac.21660
19. Nag S, Aggarwal S, Rauthan A, Warriar N. Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review. *J Ovarian Res*. 2022 Dec 28;15(1):88. doi:10.1186/s13048-022-01020-1

20. Oliveira LRLB de, Horvat N, Andrieu PIC, Panizza PSB, Cerri GG, Viana PCC. Ovarian cancer staging: what the surgeon needs to know. *Br J Radiol*. 2021 Sep 1;94(1125). doi:10.1259/bjr.20210091
21. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. *American Journal of Surgical Pathology*. 2020 Mar;34(3):433–43. doi:10.1097/PAS.0b013e3181cf3d79
22. Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG. Epithelial ovarian cancer risk: A review of the current genetic landscape. *Clin Genet*. 2020 Jan 29;97(1):54–63. doi:10.1111/cge.13566
23. Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. *Semin Oncol Nurs*. 2019 Apr;35(2):151–6. doi:10.1016/j.soncn.2019.02.001 PubMed PMID: 30867104.
24. Liao Y, Tu C, Song X, Cai L. Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family. *J Assist Reprod Genet*. 2020 Jun 30;37(6):1489–95. doi:10.1007/s10815-020-01783-w
25. Urzúa U, Marín A, Castellón EA. Oxidative stress, parity history, and remnant follicles in the aged ovary: insights on ovarian cancer risk and protection. *Antioxidants*. 2025 Jun 20;14(7):759. doi:10.3390/antiox14070759
26. Handoko AL, Jayadi T, Putra ERK, Kusumosih TAR. Hubungan antara obesitas dengan kanker ovarium di rumah sakit bethesda yogyakarta. *Jurnal Kedokteran Meditek*. 2023 Jan 14;29(1):27–33. doi:10.36452/jkdoktmeditek.v29i1.2544
27. Hathaway CA, Wang T, Townsend MK, Vinci C, Jake-Schoffman DE, Saeed-Vafa D, et al. Lifetime exposure to cigarette smoke and risk of ovarian cancer by t-cell tumor immune infiltration. *Journal Cancer Epidemiology, Biomarkers & Prevention*. 2023 Jan 9;32(1):66–73. doi:10.1158/1055-9965.EPI-22-0877
28. Mustafin C, Vesnin S, Turnbull A, Dixon M, Goltsov A, Goryanin I. Diagnostics of ovarian tumors in postmenopausal patients. *Diagnostics*. 2022 Oct 28;12(11). doi:10.3390/diagnostics12112619 PubMed PMID: 36359464.
29. Arora T, Mullangi S, Vadakekut ES, Lekkala MR. Epithelial ovarian cancer. 2024th ed. StatPearls Publishing; 2025. PubMed PMID: 33620837.

30. Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P. Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging. *AJR Am J Roentgenol.* 2016 Jun;206(6):1351–60. doi:10.2214/AJR.15.15199 PubMed PMID: 27042752.
31. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. *International Journal of Gynecology & Obstetrics.* 2021 Oct 20;155(S1):61–85. doi:10.1002/ijgo.13878
32. Vanderpuye VD, Clemenceau JR V., Temin S, Aziz Z, Burke WM, Cevallos NL, et al. Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: asco resource-stratified guideline. *JCO Glob Oncol.* 2021 Dec;(7):1032–66. doi:10.1200/GO.21.00085
33. Ghose A, McCann L, Makker S, Mukherjee U, Gullapalli SVN, Erekkath J, et al. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. *Ther Adv Med Oncol.* 2024 Jan 29;16:1–12. doi:10.1177/17588359241233225
34. Hattrup CL, Gendler SJ. Structure and function of the cell surface (Tethered) mucins. *Annu Rev Physiol.* 2008 Mar 1;70(1):431–57. doi:10.1146/annurev.physiol.70.113006.100659
35. Scholler N, Urban N. CA125 in ovarian cancer. *Biomark Med.* 2007 Dec 17;1(4):513–23. doi:10.2217/17520363.1.4.513
36. Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, et al. Large prospective study of ovarian cancer screening in high-risk women: ca125 cut-point defined by menopausal status. *Cancer Prevention Research.* 2011 Sep 1;4(9):1401–8. doi:10.1158/1940-6207.CAPR-10-0402
37. Mukama T, Fortner RT, Katzke V, Hynes LC, Petrera A, Hauck SM, et al. Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer. *Br J Cancer.* 2022 May 18;126(9):1301–doi:10.1038/s41416-021-01697-z
38. Gentry-Maharaj A, Blyuss O, Ryan A, Burnell M, Karpinskyj C, Gunu R, et al. Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women. *Cancers (Basel).* 2020 Jul 1;12(7):1–12. doi:10.3390/cancers12071931
39. Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. *J Cancer.* 2014;5(1):25–30. doi:10.7150/jca.7810

40. Giuliani M, Gui B, Valentini AL, Di Giovanni SE, Miccò M, Rodolfo E, et al. Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery. Correlation between CT findings and CA 125 levels. *Journal Minerva Obstetrics and Gynecology*. 2017 Oct;69(6). doi:10.23736/S0026-4784.17.04062-X
41. Gadducci A, Cosio S. Surveillance of patients after initial treatment of ovarian cancer. *Journal Critical Reviews in Oncology/Hematology*. 2009 Jul;71(1):43–52. doi:10.1016/j.critrevonc.2008.12.008
42. Cheng Z, Yan M, Lu Y, Pan XT. Expression of serum BMP6 and hepcidin in cancer-related anemia. *Hematology*. 2020 Jan 1;25(1):134–8. doi:10.1080/16078454.2020.1738098
43. Obeagu EI. Hemoglobin and human longevity: integrating oxygen transport, redox biology, and aging pathways – a narrative review. *Annals of Medicine & Surgery*. 2026 Jan;88(1):580–6. doi:10.1097/MS9.0000000000004508
44. Xu Y, Yu Z, Liu H, Bian X, Tang W. Erythrocytes enhance oxygen-carrying capacity through self-regulation. *Front Physiol*. 2025 May 16;16. doi:10.3389/fphys.2025.1592176
45. Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. *J Clin Invest*. 2022 Jun 1;132(11). doi:10.1172/JCI159839 PubMed PMID: 35642641.
46. Boussios S, Karathanasi A, Zakythinakis-Kyriakou N, Tsiouris AK, Chatziantoniou AA, Kanellos FS, et al. Ovarian carcinosarcoma: current developments and future perspectives. *Crit Rev Oncol Hematol*. 2019 Feb;134:46–55. doi:10.1016/j.critrevonc.2018.12.006
47. Moch H. Female genital tumours: who classification of tumours. WHO classification of tumours. 5th Edition. International Agency for Research on Cancer; 2020. 632 p.
48. Sambasivan S. Epithelial ovarian cancer: Review article. *Cancer Treat Res Commun*. 2022;33. doi:10.1016/j.ctarc.2022.100629
49. Rahmalia K, Sudiarta KE, Setianingsih H, Diarsvitri W. The Characteristics of Sociodemography, Histopathologic Features, Stage, and Management of Ovarian Cancer in Dr. Ramelan Navy Hospital Surabaya. *Indonesian Journal of Cancer*. 2024 Jun 27;18(2):130–6. doi:10.33371/ijoc.v18i2.1050

50. Hidayat YM, Febriani EF, Harsono AB, Winarno GNA, Kurniadi A. Karakteristik Karsinoma Ovarium Pra-Menopause dengan Kadar CA 125 ≤ 200 U/mL di RSUP Dr. Hasan Sadikin Bandung dari Tahun 2019–2021. *Indonesian Journal of Obstetrics & Gynecology Science*. 2023 Jul 17;6(2):263. doi:10.24198/obgynia.v6i2.491
51. Momenimovahed Z, Mazidimoradi A, Allahqoli L, Salehiniya H. The Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review. *Cancer Rep (Hoboken)*. 2025 Mar;8(3):e70142. doi:10.1002/cnr2.70142 PubMed PMID: 40067023.
52. Diva Rahayu DR, Eko Nugroho, Maulida Julia Saputri. Hubungan Kadar CA-125 dengan Derajat Diferensiasi Kanker Ovarium Tipe Epithelial Tahun 2020 – 2022 di RSUD Abdul Wahab Sjahranie Samarinda. *Ranah Research : Journal of Multidisciplinary Research and Development*. 2024 Sep 23;6(6):2517–25. doi:10.38035/rrj.v6i6.1126
53. Ning K, Sun X, Liu L, He L. Prevalence and contributing factors of anemia in patients with gynecological cancer: a retrospective cohort study. *Sci Rep*. 2024 May 9;14(1):10628. doi:10.1038/s41598-024- 61015-4
54. Dewanto W, Harsono AB, Aziz MA. Comparing Optimal Debulking Surgery Outcomes between Anemic and Non-Anemic Ovarian Cancer Patients at Dr. Hasan Sadikin General Hospital Bandung in 2022 – 2023. *Indonesian Journal of Obstetrics & Gynecology Science*. 2025 Nov 19;8(3):489. doi:10.24198/obgynia.v8i3.948
55. Mehra P, Aditi S, Prasad KM, Bariar N k. Histomorphological Analysis of Ovarian Neoplasms According to the 2020 WHO Classification of Ovarian Tumors: A Distribution Pattern in a Tertiary Care Center. *Cureus*. 2023 Apr 28. doi:10.7759/cureus.38273
56. Zaen WIUEN, Agustiansyah P, Oktharina EH, Sanif R, Purnamasari S. Characteristics of Epithelial Ovarian Cancer at RSUP Dr. Mohammad Hoesin Palembang Period from January 2020 to September 2023. *Indonesian Journal of Obstetrics & Gynecology Science*. 2025 Mar 20;8(1):58. doi:10.24198/obgynia.v8i1.762
57. Hufnagel DH, Mehta ST, Ezekwe C, Brown AJ, Beeghly-Fadiel A, Prescott LS. Prevalence of Anemia and Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia in Patients With Gynecologic Cancer. *Journal of the National Comprehensive Cancer Network*. 2021 May;19(5):513–20. doi:10.6004/jnccn.2020.7638

58. Ning K, Sun X, Liu L, He L. Prevalence and contributing factors of anemia in patients with gynecological cancer: a retrospective cohort study. *Sci Rep.* 2024 Dec 1;14(1). doi:10.1038/s41598-024-61015-4 PubMed PMID: 38724572.
59. Dewanto W, Harsono AB, Aziz MA. Comparing Optimal Debulking Surgery Outcomes between Anemic and Non-Anemic Ovarian Cancer Patients at Dr. Hasan Sadikin General Hospital Bandung in 2022 – 2023. *Indonesian Journal of Obstetrics & Gynecology Science.* 2025 Nov 19;8(3):489. doi:10.24198/obgynia.v8i3.948

